Global Search
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Reference Materials

Mucopolysaccharidoses Type I Gene Therapy

key information

source: Journal of inherited metabolic disease

year: 2021

authors: Hurt SC,Dickson PI,Curiel DT

summary/abstract:

Mucopolysaccharidoses type I (MPS I) is an inherited metabolic disease characterized by a malfunction of the α-l-iduronidase (IDUA) enzyme leading to the storage of glycosaminoglycans in the lysosomes. This disease has longtime been studied as a therapeutic target for those studying gene therapy and many studies have been done using various vectors to deliver the IDUA gene for corrective treatment. Many vectors have difficulties with efficacy and insertional mutagenesis concerns including adeno-associated viral (AAV) vectors. Studies of AAV vectors treating MPS I have seemed promising, but recent deaths in gene therapy clinical trials for other inherited diseases using AAV vectors have left questions about their safety. Additionally, the recent modifications to adenoviral vectors leading them to target the vascular endothelium minimizing the risk of hepatotoxicity could lead to them being a viable option for MPS I gene therapy when coupled with gene editing technologies like CRISPR/Cas9.

organization: Cancer Biology Division, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

DOI: 10.1002/jimd.12414

read more

Related Content

© 2023 rareLife solutions Inc.